Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous TIL therapy in advanced melanoma
NCT05098184Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Sep 2021
- Primary completion
- Sep 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MDA-TIL in melanoma, sponsored by Juncell Therapeutics. Primary endpoints: Adverse Events at 6 months, Objective Response Rate at 36 months and 4 more. Started Sep 2021; status: recruiting.
02
Drugs
MDA-TIL
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05098184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05098184.